×
Poseida Therapeutics EBIT 2019-2024 | PSTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Poseida Therapeutics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Poseida Therapeutics EBIT 2019-2024 | PSTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Poseida Therapeutics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$150.5B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$115.4B
Gilead Sciences (GILD)
$109.4B
CSL (CSLLY)
$85.4B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$34.4B
Alnylam Pharmaceuticals (ALNY)
$30.2B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$22.6B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$18.3B
Moderna (MRNA)
$14.3B
Incyte (INCY)
$13.6B
Genmab (GMAB)
$13.6B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.8B
Vaxcyte (PCVX)
$10.9B
Bio-Techne Corp (TECH)
$10.5B
Sarepta Therapeutics (SRPT)
$10.2B
Exact Sciences (EXAS)
$10B
Exelixis (EXEL)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
QIAGEN (QGEN)
$9.3B
Intra-Cellular Therapies (ITCI)
$8.8B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$7.5B
Repligen (RGEN)
$7.2B